VYCELLIX INC has a total of 18 patent applications. It decreased the IP activity by 57.0%. Its first patent ever was published in 2016. It filed its patents most often in Australia, Brazil and Canada. Its main competitors in its focus markets pharmaceuticals and biotechnology are HUMAN GENE THERAPY RESEARCH IN, JAPAN AS REPRESENTED BY THE DIRECTOR GENERAL OF NAT INSTITUTE OF INFECTIOUS DISEASES and OXXON THERAPEUTICS LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 2 | |
#2 | Brazil | 2 | |
#3 | Canada | 2 | |
#4 | China | 2 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | Israel | 2 | |
#7 | Republic of Korea | 2 | |
#8 | United States | 2 | |
#9 | WIPO (World Intellectual Property Organization) | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Alici Evren | 14 |
#2 | Sutlu Tolga | 7 |
#3 | Duru Adil | 7 |
#4 | Evren Alici | 2 |
#5 | Tolga Sutlu | 1 |
#6 | Adil Duru | 1 |
Publication | Filing date | Title |
---|---|---|
CN108883124A | For enhancing the novel RNA construct and method of cytotoxic cell and stem cell curative effect | |
EP3356524A2 | Enhanced gene delivery to natural killer cells, hematopoietic stem cells and macrophages |